Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy

Journal of Clinical Sleep Medicine

Volumn 11, Issue 4, 2015, Pages 427-432

  Bogan, Richard K ^a   Roth, Thomas ^b   Schwartz, Jonathan ^c   Miloslavsky, Maja ^d  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d JAZZ PHARMACEUTICALS   (United States)

Author keywords

Cataplexy; Excessive daytime sleepiness; Narcolepsy; Sodium oxybate; Time to response

Indexed keywords

OXYBATE SODIUM; PLACEBO; HYPNOTIC SEDATIVE AGENT;

ADULT; ARTICLE; CATAPLEXY; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DOUBLE BLIND PROCEDURE; EPWORTH SLEEPINESS SCALE; EXCESSIVE DAYTIME SLEEPINESS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; DISORDERS OF EXCESSIVE SOMNOLENCE; TIME FACTOR; TREATMENT OUTCOME;

ADULT; DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; NARCOLEPSY; SODIUM OXYBATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927939676     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.4598     Document Type: Article

References (16)

1. Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med 2014;15:502-7.
2. Rosenberg R, Kim AY. The AWAKEN Survey: knowledge of narcolepsy among physicians and the general population. Postgrad Med 2014;126:78-86.
3. De la Herran-Arita AK, Garcia-Garcia F. Narcolepsy as an immune-mediated disease. Sleep Disord 2014:792687.
4. National Institute of Neurological Disorders and Stroke. Narcolepsy Fact Sheet. Bethesda, MD: National Institutes of Health, 2013.
5. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1705-11.
6. Xyrem [sodium oxybate] oral solution US prescribing information. Palo Alto, CA: Jazz Pharmaceuticals, Inc., April 2014.
7. U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates longterm efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-23.
8. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006;29:939-46.
9. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1:391-7.
10. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebocontrolled study in 228 patients. Sleep Med 2005;6:415-21.
11. The US Xyrem Multi-Center Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-9.
12. U.S. Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26:31-5.
13. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-5.
14. Steffen AD, Lai C, Weaver TE. Development of a definition of response to narcolepsy treatment. Sleep 2014;37(Abstract Suppl):A361.
15. Guilleminault C, Fromherz S. Narcolepsy: diagnosis and management. In: Kryger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine. 5th ed. Philadelphia, PA: Elsevier Saunders, 2011.
16. Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics 2012;9:739-52.